Abstract:BackgroundMyricetin (MYR) is a polyhydroxy flavone originally isolated from Myrica rubra, and is widely distributed in a variety of medicinal plants and delicious food. MYR has been proven to have inhibitory effects against various types of cancer. However, the exact role of MYR in lymphoma development is still unclear.MethodsIn vitro, the MTT assay was performed to evaluate the activity of human diffuse large B lymphoma cell TMD-8 and other tumor cells. Homogeneous time-resolved fluorescence (HTRF) and molecular docking were used to detect the target of MYR inhibiting TMD-8 cells. In addition, flow cytometry, Annexin V-FITC/PI assays, Hoechst 33258, and mondansylcadaverine (MDC) fluorescent standing were used to detect the cell cycle, apoptosis, and autophagy, respectively. Moreover, Western blot analysis was conducted to analyze related signaling pathways. In TMD-8 cell xenotransplanted mice, immunohistochemistry, histopathology, and blood biochemical tests were used to evaluate the effectiveness and safety of oral administration of MYR.ResultsHere, we found that MYR is more sensitive to TMD-8 cells than other tumor cells by targeting bruton tyrosine kinase (BTK). BTK is an attractive target for the treatment of B-cell malignancies. The HTRF assay showed that MYR inhibited BTK kinase with an IC50 of 1.82 μM. Furthermore, the HTRF assay and Western blot analysis demonstrated that MYR could bind to key residues (Ala478, Leu408, Thr474) in the BTK active pocket, inhibit the autophosphorylation on tyrosine 223, and block BTK/ERK and BTK/AKT signal transduction cascades (including downstream substrates GSK-3β, IKK, STAT3, and NF-κb). The results of cell cycle, apoptosis, and autophagy showed that MYR could induce G1/G0 cycle arrest by regulating cyclinB1/D1 expression, induce apoptosis by increasing the Bax/Bcl-2 ratio, and trigger autophagy by inhibiting mTOR activation. In vivo, oral administration of MYR significantly inhibited the growth of TMD-8 xenograft tumora without toxic side effects. Furthermore, Ki67 and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis showed that MYR could inhibit proliferation and induce apoptosis of tissue lymphoma cells.ConclusionTaken together, MYR is an oral available natural BTK inhibitor that effectively inhibits the growth of lymphoma TMD-8 cells both in vitro and in vivo. In addition, our findings support that the use of MYR is a novel and promising therapeutic strategy for the treatment of lymphoma.

Potential Anticancer Activity of Myricetin in Human T24 Bladder Cancer Cells Both in Vitro and in Vivo

Myricetin Inhibits Proliferation of Cisplatin-Resistant Cancer Cells Through a P53-Dependent Apoptotic Pathway

Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex.

Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells

EFFECTS OF MYRICETIN ON HUMAN LUNG ADENOCARCINOMA CELL LINES AND ITS MECHANISM

Genipin Inhibits the Growth of Human Bladder Cancer Cells Via Inactivation of PI3K/Akt Signaling.

Resveratrol Induces Apoptosis and Cell Cycle Arrest of Human T24 Bladder Cancer Cells in Vitro and Inhibits Tumor Growth in Vivo

Myricetin: versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS–reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction

Thymol Inhibits Bladder Cancer Cell Proliferation Via Inducing Cell Cycle Arrest and Apoptosis

INHIBITION OF MYRICETIN ON HUMAN LUNG ADENOCARCINOMA H460 CELL PROLIFERATION AND THE ROLE OF ERK PATHWAY

Myricetin Induces Apoptosis In Hepg2 Cells Through Akt/P70s6k/Bad Signaling And Mitochondrial Apoptotic Pathway

Matrine Inhibits Invasiveness and Metastasis of Human Malignant Melanoma Cell Line A375 in Vitro

Inhibition effects and induction of apoptosis of flavonoids on the prostate cancer cell line PC-3 in vitro

Anti-proliferative and Apoptotic Effects of S1, a Tetrandrine Derivative, in Human Gastric Cancer BGC-823 Cells

Myricetin inhibits 4 T1 breast tumor growth in mice via induction of Nrf-2/GPX4 pathway-mediated Ferroptosis

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.

Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo

Myricetin Suppresses Ovarian Cancer In Vitro by Activating the p38/Sapla Signaling Pathway and Suppressing Intracellular Oxidative Stress

Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

Anticancer effect of myristicin on hepatic carcinoma and related molecular mechanism

Myricetin Induces Apoptosis and Protective Autophagy through Endoplasmic Reticulum Stress in Hepatocellular Carcinoma